

## Contents

---

<i>Preface</i> .....	(vii)
<i>Acknowledgement</i> .....	(ix)
<i>Abbreviations</i> .....	(xxxix)

### PART I

#### GENERAL PRINCIPLES

##### Chapter - 1

##### Branches and Divisions of Pharmacology

Introduction .....	3
Drug .....	3
Drug Sources .....	4
Drug Nomenclature .....	4
The Nature of Drugs .....	4
Branches of Pharmacology .....	5
Hypersensitivity .....	9
Type I Hypersensitivity .....	9
Type II Hypersensitivity .....	10
Type III Hypersensitivity .....	10
Type IV Hypersensitivity .....	11
Drug Response and Factors affecting Drug Response .....	12
Important Factors Modifying Drug Action .....	12

##### Chapter - 2

##### Pharmacokinetics of Drugs

Biotransport of Drug .....	22
Composition and Structure of Membranes .....	22
Lipids .....	22

Proteins .....	23
Transfer through the Lipid Bilayer .....	23
Transfer through Membrane Protein Structures .....	25
Transport by Exocytosis and Endocytosis .....	26
Drug Absorption .....	27
Distribution of Drugs .....	30
Drug Distribution from Blood .....	31
Binding to Proteins .....	31
Tissue Distribution of Drugs .....	32
Excretion of Drugs .....	34
Different Routes of Drug Excretion .....	35
Other Routes of Excretion .....	38
Milk Excretion .....	38
Sweat Excretion .....	38
Mammary Excretion .....	38
Excretion by various Secretions .....	38
Artificial Methods of Excretion .....	39
Digestive Excretion .....	39
Accelerated Renal Excretion .....	39
Artificial Excretion .....	39
Theoretical Pharmacokinetics .....	39
References .....	41

##### Chapter - 3

##### Drug Receptors and Pharmacodynamics

Introduction .....	42
Drug-Receptor Complex Nomenclature .....	42
Some Characteristics of Receptors .....	43
Drug Receptor Interactions .....	55
Receptor Site Theories .....	56
Pharmacodynamics .....	57
References .....	59

**Chapter - 4**

**Drug Biotransformation**

Introduction ..... 60  
  Sites of Drug Metabolism ..... 60  
  Drug Metabolizing Enzymes ..... 61  
  Phase I Reactions ..... 62  
  Oxidative Reactions ..... 64  
  Reductive Reactions ..... 68  
  Hydrolytic Reactions ..... 68  
  Phase II Reactions ..... 70  
Factors Affecting  
Biotransformation of Drug ..... 77  
  Enzyme Inhibition ..... 78  
  Presystemic Metabolism/First Pass  
  Effect/Route of Administration ..... 79  
  Genetic Variations ..... 79  
  Species Differences ..... 79  
  Exposure to Pollutants from  
  Environment or Industry ..... 79  
  Age ..... 79  
  Sex ..... 80  
  Drug-Drug Interaction ..... 80  
  Nutrition ..... 80  
  Pathological Conditions ..... 80  
  Circadian Rhythm ..... 80  
References ..... 80

**PART II**

**DRUGS AFFECTING AUTONOMIC  
NERVOUS SYSTEM**

**Chapter - 5**

**General Considerations of  
Autonomic Nervous System**

Anatomy ..... 83  
Sympathetic Division ..... 83  
Parasympathetic Division ..... 84  
Sensory Neurons ..... 85  
Motor Neurons ..... 85  
Function ..... 86  
  Sympathetic Nervous System ..... 86  
  Parasympathetic Nervous System ..... 86  
Neurotransmitters and Pharmacology ... 86  
References ..... 89

**Chapter - 6**

**Cholinergic Drugs**

The Cholinergic Neuron ..... 90  
  Neurotransmission at  
  Cholinergic Neurons ..... 90  
Cholinergic Receptors  
(Cholinoceptors) ..... 92  
  Muscarinic Receptors (M) ..... 92  
  Molecular Mechanism at  
  Muscarinic Receptors ..... 92  
  Nicotinic Receptors ..... 93  
  Molecular Mechanisms/Signal  
  Transduction at Nicotinic Receptors ..... 93  
  Parasympathomimetic Drugs or  
  Cholinergic Drugs or  
  Cholinomimetic Drugs ..... 93  
  Acetylcholine Effects ..... 95  
  Muscarinic Effects ..... 95  
  Cardiac Effects ..... 95  
  Vascular Effects ..... 95  
  Effects on Smooth Muscles  
  (Except Vascular) ..... 95  
  Effects on Secretions (Receptors M<sub>3</sub>) ..... 96  
  Effects on the Eye (Receptors M<sub>3</sub>) ..... 96  
  Central Effects ..... 96  
  Nicotinic Effects ..... 96  
  Autonomic Ganglia Effects ..... 96  
  Neuromuscular Junction Effects ..... 96  
  Central Nervous System Effects ..... 98  
Parasympathomimetic Drugs ..... 98  
  Directly acting Cholinergic Drugs ..... 98  
  Cholinomimetic Alkaloids ..... 99  
  Acetylcholinesterase ..... 102  
  Reversible Inhibitors ..... 102  
  Mechanisms of Action of Indirect  
  (Reversible) Cholinergic Agonists ..... 104  
  Irreversible Inhibitors ..... 104  
  Anticholinesterase/Organophosphorus  
  Poisoning and Treatment ..... 105  
References ..... 106

**Chapter - 7**

**Muscarinic Receptor Blocking Drugs**

Classification ..... 107  
Basic Pharmacology of Muscarinic  
Receptor Blocking Drugs ..... 108  
  Pharmacokinetics ..... 108

Mechanism of Action ..... 108  
 Effects ..... 108  
 Toxicity of Antimuscarinic Drugs ..... 112  
     Predictable Toxicities ..... 112  
     Unpredictable Toxicities ..... 112  
 Clinical Uses ..... 112  
     Mydriatic Agents ..... 112  
     Gastric Acid Secretion Inhibitors ..... 112  
     Bronchodilators ..... 113  
     With Vesical Indications ..... 113  
     Used as Antispasmodics ..... 113  
     Used as Antiparkinsonians ..... 113  
     Uses in Urology ..... 113  
     Uses in Anaesthesiology ..... 113  
     Other Drugs ..... 116  
 Contraindications and Cautions ..... 116  
 References ..... 116

**Chapter - 8**  
**Adrenergic Drugs**

The Adrenergic Neuron ..... 117  
     Neurotransmission at  
     Adrenergic Neurons ..... 117  
 Synthesis, Storage and  
 Release of Catecholamines ..... 118  
 Metabolism and Distribution  
 of Catecholamines ..... 119  
 Adrenergic Receptors ..... 119  
      $\alpha$  Receptors ..... 121  
      $\beta$  Receptors ..... 121  
 Classification of Adrenergic Agonists . 122  
     Structure Activity Relationship of  
     Adrenergic Drugs ..... 123  
 Direct-Acting Agonists ..... 124  
     Epinephrine (EP) ..... 124  
     Norepinephrine (NE) ..... 126  
     Dopamine ..... 127  
     Amphetamine ..... 128  
     Ephedrine ..... 128  
     Isoproterenol ..... 129  
 Selective Adrenergic Agonists ..... 129  
     Phenylephrine, Metaraminol,  
     and Methoxamine ..... 129  
     Dobutamine ..... 129  
     Terbutaline and Albuterol ..... 130  
 References ..... 130

**Chapter - 9**  
**Adrenergic Blocking Drugs**

Classification of  
 Sympatholytic Drugs ..... 131  
 Alpha-Adrenergic  
 Antagonists (Blockers) ..... 131  
     Classification ..... 131  
     Quinazoline Derivatives ..... 131  
     Imidazoline Derivative ..... 133  
     Haloalkylamines ..... 133  
     Clinical Pharmacology of  $\alpha$ -receptor  
     Blocking Drugs ..... 134  
      $\beta$ -Adrenergic Antagonists ..... 135  
     Nonselective- $\beta$  Adrenergic  
     Receptor Antagonists ..... 139  
     Selective- $\beta_1$  Adrenergic Receptor  
     Antagonists ..... 139  
     Therapeutic uses for Beta Adrenergic  
     Receptor Antagonists (Blockers) ..... 140  
     Hyperthyroidism ..... 140  
     Glaucoma ..... 140  
     Anxiety States ..... 141  
     Migraine ..... 141  
     Angina Pectoris ..... 141  
     Acute Myocardial Infarction ..... 141  
     Supraventricular Tachycardias and  
     Ventricular Dysrhythmias ..... 141  
     Hypertension ..... 141  
     Adverse Effects of  $\beta$  Adrenergic  
     Receptor Antagonists ..... 142  
     Drugs with Combined  $\alpha$ -and  
      $\beta$ -Blocking Activity ..... 142  
     Labetalol ..... 142  
     Other Compounds ..... 144  
 References ..... 144

**Chapter - 10**  
**Ganglionic Stimulating and  
 Blocking Agents**

Introduction ..... 145  
     Mechanism of Action ..... 145  
 Pharmacological Actions ..... 146  
     Peripheral Nervous System ..... 146  
     Central Nervous System ..... 146  
     Cardiovascular System ..... 147  
     Gastrointestinal Tract ..... 147  
     Exocrine Glands ..... 147

Pharmacokinetics ..... 147  
Acute Nicotine Poisoning ..... 147  
Therapy ..... 148  
Lobeline ..... 148  
Other Ganglionic Stimulants ..... 148  
Ganglion-Blocking Drugs ..... 149  
Classification ..... 149  
Chemistry and Pharmacokinetics ..... 149  
Pharmacodynamics ..... 150  
Organ System Effects ..... 150  
Clinical Applications and Toxicity ..... 150  
References ..... 152

**Chapter - 11**

**Skeletal Muscle Relaxants**

Introduction ..... 153  
Neuromuscular Physiology ..... 153  
Classification ..... 154  
Mechanism of Skeletal  
Muscle Contraction ..... 154  
Nondepolarizing Agents ..... 155  
Mechanism of Action ..... 155  
Pharmacological Actions ..... 155  
Clinical Uses ..... 155  
Adverse Effects and Precautions ..... 155  
Other Nondepolarizing  
Blockers of Importance ..... 156  
Classification According to  
Duration of Action ..... 156  
Depolarizing Agents ..... 158  
Drugs: Suxamethonium  
(succinylcholine) Decamethonium ..... 158  
Succinylcholine ..... 158  
Uses of Neuromuscular  
Blocking Drugs ..... 160  
Central Acting Skeletal Muscle  
Relaxants (Spasmolytic Drugs) ..... 161  
Methocarbamol ..... 162  
Baclofen ..... 162  
Dantrolene ..... 162  
Botulinum Toxin Type A,B ..... 162  
Benzodiazepines (diazepam,  
lorazepam, clonazepam, etc.) ..... 163  
Tizanidine ..... 163

Drugs Used to Treat Acute  
Local Muscle Spasm ..... 163  
Cyclobenzaprine ..... 164  
Orphenadrine ..... 165  
Metaxalone ..... 165  
Carisoprodol ..... 165  
Other Centrally Acting  
Spasmolytic Drugs ..... 165  
References ..... 165

**PART III**

**DRUGS AFFECTING  
CENTRAL NERVOUS SYSTEM**

**Chapter - 12**

**General Considerations of  
Central Nervous System**

Macroanatomy ..... 169  
Microanatomy of the Brain ..... 170  
Central Neurotransmitters ..... 171  
Biogenic Amines ..... 171  
Acetylcholine ..... 178  
GABA and Glycine ..... 178  
Amino Acids ..... 185  
Neuropeptides (polypeptides) ..... 187  
Purine Nucleotides ..... 187  
P<sub>2</sub> Receptors and Actions ..... 189  
Peptides ..... 190  
References ..... 191

**Chapter - 13**

**Neurodegenerative Diseases**

Introduction ..... 192  
Alzheimer's Disease ..... 192  
Pathophysiology ..... 192  
Symptoms ..... 193  
Treatment ..... 193  
Parkinson's Disease ..... 195  
Pathophysiology ..... 195  
Symptoms ..... 195  
Treatment ..... 196  
Huntington Disease ..... 205  
Symptoms and Stages of HD ..... 205  
The Stages of HD ..... 206  
Diagnosis ..... 207

Juvenile Huntington’s Disease ..... 207  
 Symptomatic Treatment and Management ..... 207  
 References ..... 210

**Chapter - 14**  
**General Anaesthetics**

Principle of General Anaesthesia ..... 212  
 Stages of Anesthesia ..... 212  
 Theory of General Anaesthetics ..... 214  
 Lipid Theory ..... 214  
 Classification ..... 215  
 Intravenous Anesthetics or Induction Agents ..... 215  
 Inhaled Anaesthetics ..... 220  
 Preanaesthetic Medication ..... 226  
 Objectives of Preanaesthetic Medication ..... 226  
 Sedatives/ Anxiolytics ..... 226  
 Opioid Analgesics ..... 227  
 Anticholinergic Drugs ..... 227  
 Antiemetics–Antiemetic Effect ..... 227  
 References ..... 228

**Chapter - 15**  
**Sedative Hypnotics and Anxiolytic Drugs**

Sleep ..... 229  
 Genesis of Sleep ..... 229  
 Classification ..... 230  
 Azapirones ..... 230  
 Benzodiazepines ..... 231  
 Barbiturates ..... 236  
 Other Benzodiazepine Receptor Agonists ..... 238  
 Sedatives and Anxiolytics with other Major Uses ..... 238  
 Antihistamines ..... 238  
 $\beta$  - Adrenoceptor Blocking Agents.. 239  
 Antidepressants ..... 239  
 Older Sedative-Hypnotics and Anxiolytic Agents ..... 239  
 Non-prescription Drugs ..... 239  
 References ..... 240

**Chapter - 16**  
**Neuroleptics**

Introduction ..... 241  
 Schizophrenia ..... 241  
 Symptoms ..... 241  
 Types ..... 242  
 Theories of Schizophrenia ..... 242  
 Dopamine Hypothesis ..... 242  
 Serotonin Hypothesis ..... 242  
 Glutamate Hypothesis ..... 243  
 Definitions ..... 243  
 Ideal Antipsychotic ..... 243  
 Classification of Antipsychotic Drugs ..... 243  
 Distinction between ‘typical’ and ‘atypical’ groups is not clearly defined, but rests on: ..... 243  
 Mechanism of Action ..... 244  
 Phenothiazines ..... 245  
 Chlorpromazine ..... 245  
 Pharmacological Effects and Mechanism ..... 246  
 Pharmacokinetics ..... 246  
 Adverse Effects ..... 246  
 Therapeutic Uses ..... 247  
 Phenothiazines - Drug Interactions ..... 249  
 Nonphenothiazines ..... 249  
 First-Generation “Typical” Antipsychotics ..... 249  
 Second-Generation “Atypical” Antipsychotics ..... 249  
 References ..... 253

**Chapter - 17**  
**Antidepressants**

Introduction ..... 254  
 Causes for Depression ..... 254  
 The Monoamine Theory ..... 254  
 Symptoms ..... 254  
 Treatment ..... 255  
 Classification ..... 255  
 Antidepressants ..... 255  
 Selective Serotonin Reuptake Inhibitors ..... 255  
 Mechanism of Action ..... 255

Pharmacokinetics .....	256	Lamotrigine .....	269
Therapeutic Uses .....	256	Zonisamide .....	269
Adverse Effects .....	256	Topiramate .....	270
Drug Interactions .....	257	Sodium Valproate or Valproic Acid .....	270
Serotonin-Norepinephrine Reuptake Inhibitors .....	257	Drugs that Primarily Enhance the Action of GABA .....	271
Types of SNRIs .....	257	Benzodiazepines .....	271
Mechanism of Action .....	257	Vigabatrin .....	272
Adverse Effects .....	257	Tiagabine .....	272
Atypical Antidepressants .....	257	Phenobarbital and Primidone (Mysoline) .....	272
Mechanism of Action .....	257	Agents that Block T-Calcium Channels .....	273
Atypical Antidepressants Approved to Treat Depression .....	258	Ethosuximide .....	273
Adverse Effects of Atypical Antidepressants .....	258	Agents whose Mechanism of Action is not Known .....	273
Tricyclic and Tetracyclic Antidepressants .....	258	Felbamate .....	273
Mechanism of Action .....	258	Gabapentin .....	273
Cyclic Antidepressants Approved to Treat Depression .....	258	Levetiracetam .....	274
Adverse Effects of Tricyclic Antidepressants .....	259	Anticonvulsant Drugs and Pregnancy ..	274
MAO Inhibitors .....	259	Treatment of Febrile Seizures .....	275
Mechanism of Action .....	259	Treatment of Status Epilepticus .....	275
Risks are Associated with MAO Inhibitors .....	259	References .....	275
Medications to Avoid .....	259	<b>Chapter - 19</b> <b>Opioid Analgesics</b>	
Foods to Avoid .....	260	Introduction .....	276
Adverse Effects .....	260	Endogenous Opioids .....	277
References .....	260	Enkephalins, Endorphins, Dynorphins, Endomorphins .....	278
<b>Chapter - 18</b> <b>Antiepileptic Drugs</b>		Opioid Receptors .....	278
Introduction .....	261	Mechanism of Opioid Receptor Function .....	279
Pathophysiology .....	261	Classification of Opioid Analgesic Drugs .....	279
Types of Seizures .....	261	Pharmacokinetics .....	279
Partial Seizures .....	261	Cellular Mechanisms of Action .....	280
Generalised Seizures .....	262	Pharmacological Effects .....	280
Causes for Acute Seizures .....	263	Tolerance and Physical Dependence ..	281
Treatment .....	264	Morphine .....	282
Strategies .....	264	Other Opioids .....	283
Classification of Antiepileptics .....	265	Meperidine or Pethidine .....	283
Sodium Channel Blocking Agents .....	267	Methadone .....	284
Phenytoin .....	267	Fentanyl .....	284
Carbamazepine .....	268	Heroin .....	284
Oxcarbazepine .....	269	Codeine .....	284

Oxycodone .....	284	Clinical Uses, Adverse Effects and Contraindications .....	299
Propoxyphene .....	285	Ibuprofen .....	299
Mixed Agonist-Antagonist and Partial Agonists .....	285	Fenoprofen .....	299
Buprenorphine .....	285	Naproxen .....	299
Pharmacokinetics .....	285	Ketoprofen .....	300
Antagonists .....	286	Flurbiprofen .....	300
References .....	287	Pyrazolone Derivatives .....	300
<b>Chapter - 20</b>		Oxicam Derivatives .....	300
<b>Non Steroidal Anti-inflammatory Drugs</b>		Acetic Acid Derivatives .....	301
Introduction .....	288	Miscellaneous Agents .....	301
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) .....	289	COX-2 Inhibitors .....	302
Mechanism of Action .....	289	Chemistry .....	302
Anti-inflammatory Effect .....	289	Mechanism of Action .....	302
Analgesic Effect .....	290	Pharmacological Effects and Clinical Uses .....	302
Antipyretic Effect .....	290	Adverse Effects .....	303
Classification .....	290	Contraindications .....	303
Mechanism of Action of Non-steroidal Anti-inflammatory Drugs (NSAIDs) .....	290	Rofecoxib .....	303
Salicylates .....	290	References .....	303
Chemistry .....	290	<b>Chapter - 21</b>	
Mechanism of Action .....	291	<b>CNS Stimulants</b>	
Pharmacokinetics .....	292	Introduction .....	304
Pharmacological Effects .....	292	Classification .....	304
Overdose and Other Adverse Effects ....	293	Analeptic Stimulants .....	305
Therapeutic Uses .....	294	Mechanism of Action .....	305
Drug Interactions .....	294	Pharmacokinetics .....	306
P-Aminophenol Derivatives .....	294	Clinical Uses .....	306
Pharmacokinetics .....	294	Psychomotor Stimulants .....	306
Mechanism of Action .....	295	Pharmacokinetics .....	307
Pharmacological Effects .....	295	Clinical Uses .....	307
Adverse Effects .....	295	Adverse Effects .....	307
Therapeutic Uses .....	295	Xanthines .....	307
Contraindications .....	295	Pharmacokinetics .....	308
Indoles (indomethacin) and Related Compounds .....	296	Mechanism of Action .....	308
Chemistry and Mechanism of Action ...	296	Clinical Uses .....	309
Pharmacokinetics .....	296	Adverse Effects .....	309
Indomethacin .....	296	Abuse of Xanthines .....	309
Sulindac .....	296	Drug Interactions .....	309
Ketorolac .....	297	References .....	309
Etodolac .....	297	<b>Chapter - 22</b>	
Fenamates .....	297	<b>Drug Dependence and Drug Abuse</b>	
Arylpropionic Acid Derivatives .....	298	Opioids .....	311
Chemistry and Mechanism of Action ...	298	Extent and Pattern of Abuse .....	311

Pharmacological Aspects .....	312
Tolerance and Dependence .....	312
Treatment of Opioid Dependence .....	312
Stimulants .....	313
Extent and Pattern of Abuse .....	313
Pharmacological Aspects .....	313
Mechanism of Action .....	313
Tolerance and Dependence .....	314
Other Adverse Effects of	
Chronic Abuse .....	314
Nicotine .....	314
Sedative-Hypnotics .....	314
Pharmacological Aspects .....	314
Tolerance and Dependence .....	315
Ethanol .....	315
Chemistry .....	315
Absorption, Distribution, Metabolism	
and Excretion .....	316
Mechanism of Action .....	316
Pharmacological Actions on	
Central Nervous System .....	317
Other Body Systems .....	317
Adverse Effects .....	317
Treatment for Acute Intoxication .....	318
Alcoholism .....	318
Marijuana .....	319
Chemistry .....	319
Pharmacokinetic Aspects .....	319
Mechanism of Action .....	319
Pharmacological Actions on	
Central Nervous System .....	319
Other Organ Systems .....	320
Adverse Effects .....	320
Hallucinogens .....	320
Extent and Pattern of Abuse .....	321
Pharmacological Aspects .....	321
Tolerance and Dependence .....	322
Treatment Strategies .....	322
Mechanism of Action .....	322
Inhalants .....	322
Designer Drugs .....	323
Anabolic Steroids .....	323
References .....	323

## Chapter - 23

### Local Anaesthetics

Introduction .....	324
Chemistry .....	324
Classification .....	324
Combinations .....	325
Mechanism of Action .....	325
Various Techniques of	
Local Anesthesia .....	327
Clinical Techniques Include .....	327
Pharmacokinetics .....	328
Adverse Effects .....	329
Localized Adverse Effects .....	329
General Adverse Effects .....	329
Central Nervous System .....	329
Cardiovascular System .....	330
Hypersensitivity/Allergy .....	330
Methemoglobinemia .....	330
Specific Uses .....	330
Acute Pain .....	330
Chronic Pain .....	330
Surgery and Dentistry .....	330
Other Uses .....	331
Factors Affecting Local	
Anaesthetic Activity Clinically .....	331
Dose .....	331
Addition of Vasoconstrictors .....	331
Site of Injection .....	332
Carbonation and pH Adjustment .....	332
Mixtures of Local Anesthetics .....	332
Pregnancy .....	332
Medication Interactions with	
Local Anesthetics .....	333
References .....	333

## PART IV

### DRUGS AFFECTING ON CARDIOVASCULAR SYSTEM

## Chapter - 24

### Drugs Used in Heart Failure

Introduction .....	337
Pathophysiology of Heart Failure .....	338
Preload .....	338
Afterload .....	338



Structural Changes in Chronic CHF ..... 338	Disopyramide ..... 365
Classification of Drugs used in CHF .... 340	Moricizine ..... 367
Cardiac Glycosides ..... 341	Class IB ..... 369
Structure of Cardiac Glycosides ..... 341	Lidocaine ..... 369
Pharmacological Actions ..... 342	Phenytoin ..... 370
Therapeutic Drug Monitoring ..... 345	Tocainide ..... 371
Therapeutic uses of Digitalis ..... 346	Mexiletine ..... 372
Adverse Effects and Toxicity ..... 347	Class IC ..... 373
Other Inotropic Drugs ..... 348	Flecainide ..... 373
Dobutamine ..... 348	Propafenone ..... 374
Dopamine ..... 349	Class II ..... 376
Inodilators (Phosphodiesterase-III inhibitors) ..... 349	Propranolol ..... 376
Inamrinone (Amrinone) ..... 349	Acebutolol ..... 378
Milrinone ..... 349	Esmolol ..... 378
Enoximone ..... 350	Class III ..... 379
Role of Vasodilators in CHF ..... 350	Bretylium ..... 379
Role of Diuretics in CHF ..... 352	Amiodarone ..... 380
Vasopeptidase Inhibitors ..... 352	Sotalol ..... 382
Thiazides ..... 352	Ibutilide Fumarate ..... 384
Loop Diuretics ..... 353	Class IV ..... 385
Limitations of diuretics ..... 353	Verapamil ..... 385
Role of Aldosterone Antagonists/ K <sup>+</sup> Sparing Diuretics ..... 353	References ..... 386
Eplerenone ..... 354	
Role of Angiotensin Converting Enzyme Inhibitors (ACE-Is) ..... 354	<b>Chapter - 26</b>
Beneficial Effects of ACE-Is ..... 356	<b>Antianginal Drugs</b>
Adverse Effects of ACE-Is ..... 356	Types of Angina Pectoris ..... 387
Angiotensin Receptor Blockers (ARBs) in CHF ..... 356	Classic Angina ..... 387
Contraindications and Precautions with ACE-Is and ARBs ..... 356	Variant Angina ..... 387
References ..... 357	Unstable Angina ..... 387
	Classification of Antianginal Drugs ..... 388
	Organic Nitrates ..... 388
	Classification of Nitrates ..... 388
	Adverse Effects ..... 390
	Clinical Uses ..... 390
	Contraindications ..... 391
	Individual Nitrates ..... 391
	Beta-adrenergic Blocking Agents ..... 392
	Mechanism of Action ..... 392
	Adverse Effects ..... 393
	Therapeutic uses of Beta-Blockers ..... 393
	Contraindications ..... 393
	Calcium Channel Blocking Agents (CCBs) ..... 394
	Mechanism of Action ..... 395
	Pharmacokinetics ..... 395
	Adverse Effects ..... 395
<b>Chapter - 25</b>	
<b>Antiarrhythmic Drugs</b>	
Electrophysiology - Resting Potential .. 358	
Cardiac Action Potential ..... 359	
Arrhythmogenic Mechanisms ..... 359	
Abnormal Automaticity ..... 359	
Triggered Activity ..... 359	
Classification of Antiarrhythmic Drugs 360	
Class IA ..... 362	
Quinidine ..... 362	
Procainamide ..... 364	

Therapeutic use of  
Calcium Channel Blockers ..... 395  
Contraindications ..... 395  
Ranolazine ..... 396  
Mechanism of Action ..... 396  
Adverse Effects and Contraindications 396  
Clinical Uses ..... 397  
Adjunctive Antianginal Drugs ..... 397  
Aspirin ..... 397  
Antilipemics ..... 397  
Antihypertensives ..... 397  
Combination Therapy ..... 397  
Nitrates and Beta Blockers ..... 397  
Calcium Channel Blockers and  
Beta Blockers ..... 397  
Calcium Channel Blockers and Nitrates 397  
Drug Interactions of Antianginals ..... 397  
Nonpharmacological Management  
of Angina ..... 398  
References ..... 398

**Chapter - 27**

**Antihypertensives**

Introduction ..... 399  
Classification of  
Hypertension for Adults ..... 399  
Types of Hypertension ..... 400  
Primary Hypertension ..... 400  
Secondary Hypertension ..... 400  
Malignant Hypertension ..... 400  
Isolated Systolic Hypertension ..... 400  
White Coat Hypertension ..... 400  
Resistant Hypertension ..... 400  
Potential Sites of Action for  
Antihypertensive Drugs ..... 401  
Diuretics ..... 402  
Introduction ..... 402  
Mechanism of Action ..... 404  
Advantages ..... 404  
Special Indications ..... 404  
Chlorothiazide ..... 404  
Furosemide (Lasix), Bumetanide  
(Bumex) and Ethacrynic Acid (Edecrin) 404  
Therapeutic Uses ..... 405  
Pulmonary and Systemic Edema ..... 406  
Centrally Acting Drugs ..... 406

$\alpha$ -Methyldopa ..... 406  
Clonidine and Related Drugs ..... 407  
Adrenergic Neuron Blockers ..... 408  
Guanethidine ..... 408  
Catecholamine Depletors ..... 410  
Reserpine ..... 410  
Drugs Acting on  
Adrenergic Receptors ..... 411  
Both Alpha and  
Beta Adrenergic Blockers ..... 411  
Alpha Adrenergic Blockers ..... 411  
Beta Adrenergic Blocking Agents ..... 413  
Drugs Acting Directly on  
Vasular Smooth Muscle ..... 417  
Nitrodilators ..... 417  
Specific Drugs ..... 419  
Calcium Channel Blockers ..... 419  
Drugs Acting on  
Renin Angiotensin System ..... 422  
ACE Inhibitors ..... 422  
Angiotensin II Receptor Antagonists ... 426  
Renin Inhibitors ..... 427  
References ..... 434

**Chapter - 28**

**Hypolipidemic Drugs**

Introduction ..... 435  
Hyperlipidemia ..... 435  
Classification of  
Hypolipidemic Drugs ..... 437  
H M G - CoA Reductase  
Inhibitors (Statins) ..... 437  
Mechanism of Action ..... 437  
Pharmacological Actions ..... 439  
Adverse Effects ..... 440  
Clinical Uses ..... 440  
Contraindications ..... 440  
Drug Interactions ..... 441  
Fibric Acid Derivative (Fibrates) ..... 441  
Mechanism of Action ..... 441  
Pharmacological Actions ..... 443  
Pharmacokinetics ..... 443  
Adverse Effects ..... 443  
Clinical Uses ..... 443  
Drug Interactions ..... 444

Omega-3 Fatty Acids .....	444
Mechanism of Action .....	444
Clinical Uses .....	445
Nicotinic Acid (Niacin) .....	446
Mechanism of Action .....	446
Pharmacological Actions .....	447
Adverse Effects .....	447
Therapeutic Uses .....	447
Cholesterol Uptake Inhibitors .....	447
Ezetimibe .....	447
Bile Acid Binding Resins (BAS) .....	448
Mechanism of Action .....	449
Pharmacological Actions .....	449
Pharmacokinetics .....	449
Adverse Effects .....	449
Contraindications .....	449
Drug Interactions .....	450
Probucole .....	450
Antihyperlipidemic Combinations .....	450
Indications .....	450
Advantages .....	450
References .....	451

**PART V**

**DRUGS AFFECTING  
HAEMOSTASIS AND THROMBOSIS**

**Chapter - 29**

**Drugs and Blood Coagulation**

Introduction .....	455
Normal Haemostasis .....	455
Pathological Thrombus Formation .....	456
Blood Clotting Factors .....	456
Intrinsic Pathway .....	456
Extrinsic Pathway .....	456
Classification of Drugs .....	457
Anticoagulants .....	457
Features of an Ideal Anticoagulant .....	457
Oral Anticoagulants (Coumarin Anticoagulants) .....	457
Heparin .....	460
Newer Anticoagulants .....	464
Direct Thrombin Inhibitors (DTIs) .....	464
Hirudin and its Derivatives .....	466
Bivalirudin .....	466

Argatroban .....	467
Clinical Indications for Anticoagulant Therapy .....	469
Antiplatelet Agents .....	469
Antiplatelet Drug Targets .....	469
Aspirin .....	470
Thienopyridines .....	470
Dipyridamole .....	471
Glycoprotein IIb/IIIa Inhibitors .....	471
Thrombolytic Agents .....	471
Individual Agents .....	473
References .....	474

**Chapter - 30**

**Hemopoietic Drugs and  
Plasma Volume Expanders**

Introduction .....	475
Classification of Hematopoietic Drugs .....	475
Drugs for Anemia .....	475
Hematopoietic Growth Factors .....	475
Anemia .....	476
Causes of Anemia .....	476
Classification of Anemia .....	476
Diagnosis .....	476
Drugs for Treatment of Anemia (Hematinics) .....	477
Iron .....	477
Deferoxamine .....	479
Vitamin B <sub>12</sub> .....	479
Chemistry .....	480
Folic Acid .....	481
Hematopoietic Growth Factors .....	482
Erythropoietin .....	482
Myeloid Growth Factors (Colony Stimulating Factors - CSFs) .....	484
Megakaryocyte Growth Factors .....	485
Thrombopoietin: Eltrombopag (Promacta®) .....	486
Plasma Volume Expanders .....	487
Mechanism of Action of Plasma Volume Expanders .....	488
Ideal Plasma Expanders .....	488
Preparations of Plasma Volume Expanders .....	488
Crystalloid Fluids .....	488

Which Plasma Volume Expander is Best? ..... 496  
Potential Complications ..... 496  
References ..... 498

**PART VI**

**DRUGS AFFECTING RENAL FUNCTION**

**Chapter - 31**

**Diuretics and Antidiuretics**

Renal Physiology ..... 501  
    Glomerular Filtration ..... 501  
    Tubular Reabsorption and Secretion .... 501  
    Reabsorption ..... 501  
    Tubular Secretion ..... 502  
    Percentage of Reabsorption in Each Segment ..... 503  
Classification of Diuretics ..... 503  
Diuretics that Inhibit Transport in the Proximal Convolute Tubule ..... 505  
    Osmotic Diuretics ..... 505  
    Carbonic Anhydrase Inhibitors (CAIs) ..... 506  
Diuretics Acting on the Thick Ascending Loop of Henle (loop diuretics)/High Ceiling (most efficacious) Diuretics ..... 508  
    Mechanism of Action ..... 508  
    Effects on Electrolytes and Renal Blood Flow ..... 508  
    Pharmacokinetics ..... 509  
    Adverse Effects ..... 509  
    Therapeutic Uses ..... 510  
    Drug Interactions ..... 510  
Diuretics that Inhibit Transport in the Distal Convolute Tubule ..... 510  
    Mechanism of Action ..... 511  
    Effects on Electrolytes and Renal Haemodynamics ..... 511  
    Pharmacokinetics ..... 511  
    Adverse Effects ..... 512  
    Therapeutic Uses ..... 512  
    Drug Interactions ..... 512  
Diuretics that Inhibit Transport in the Cortical Collecting Tubule ..... 512  
    Na<sup>+</sup> Channel Inhibitors ..... 513  
    Aldosterone Antagonists ..... 513

Antidiuretic Drugs ..... 516  
    Introduction ..... 516  
    Classification ..... 516  
    Therapeutic Uses ..... 516  
Vasopressin ..... 516  
References ..... 518

**PART VII**

**DRUGS AFFECTING ENDOCRINE SYSTEM**

**Chapter - 32**

**Pituitary Hormones**

Anterior Pituitary Hormones ..... 521  
    Growth Hormone ..... 523  
    Antagonists of Growth Hormone ..... 528  
    Gonadorelin ..... 528  
    Antagonists of Gonadorelin ..... 529  
    Pituitary Hormones ..... 529  
    FSH and LH ..... 529  
    Prolactin ..... 531  
Posterior Pituitary Hormones ..... 533  
    Antidiuretic Hormone ..... 534  
    Vasopressin Antagonists ..... 536  
Oxytocin ..... 537  
    Oxytocin Antagonist ..... 538  
References ..... 539

**Chapter - 33**

**Thyroid, Parathyroid Hormones and Antithyroid Drugs**

Functional Anatomy of the Thyroid and Parathyroid Glands ..... 540  
Chemistry of Thyroid Hormones ..... 541  
    Biosynthesis of Thyroid Hormones ..... 542  
    Regulation of Thyroid Function ..... 544  
Thyroid Hormone Receptors and Mechanism of Action ..... 545  
    Mechanisms of Action of T<sub>4</sub> and T<sub>3</sub> ..... 545  
    Peripheral Metabolism of Thyroid Hormones ..... 545  
    Physiologic Effects of Thyroid Hormones ..... 545  
    Thyroid Disease States ..... 547  
Calcitonin ..... 547  
    Physiological Effects of Calcitonin ..... 548

<p>Control of Calcitonin Secretion ..... 548</p> <p>Disease States ..... 548</p> <p>Parathyroid Hormone ..... 548</p> <p>    Physiological Effects of Parathyroid Hormone ..... 548</p> <p>    Control of Parathyroid Hormone Secretion ..... 549</p> <p>    Disease States ..... 549</p> <p>    Synthetic Thyroid Hormone ..... 550</p> <p>Anti-Thyroid Drugs (ATDs) ..... 550</p> <p>    Antithyroid Agents ..... 550</p> <p>Anion Inhibitors ..... 552</p> <p>    Hormone Release Inhibitors ..... 552</p> <p>    Drugs Destroying Thyroid Tissue ..... 552</p> <p>    Miscellaneous Drugs ..... 552</p> <p>    Thyroid Storm ..... 553</p> <p>    Hyperthyroidism and Pregnancy ..... 553</p> <p>    ATD Treatment During Pregnancy and Lactation ..... 553</p> <p>    ATD Treatment of Hyperthyroidism in ..... 554</p> <p>    Children and Adolescents ..... 554</p> <p>    ATD Treatment before Thyroidectomy .. 554</p> <p>    ATDs in Thyroid Storm ..... 554</p> <p>    ATDs in Amiodarone Induced Thyrotoxicosis ..... 554</p> <p>References ..... 555</p>	<p>Treatment for Patients with Type 2 Diabetes ..... 564</p> <p>Oral Hypoglycemics ..... 565</p> <p>    Sulfonylureas ..... 565</p> <p>    Meglitinide Analogues ..... 568</p> <p>    Insulin Sensitizers ..... 568</p> <p>    <math>\alpha</math>-Glucosidase Inhibitors ..... 572</p> <p>    DPP-4 Inhibitors ..... 574</p> <p>Incretin Therapy ..... 574</p> <p>    Biosynthesis of Insulin ..... 575</p> <p>Insulins ..... 575</p> <p>    Structure of Insulin ..... 575</p> <p>    Insulin Secretion ..... 576</p> <p>    Mechanism of Action ..... 577</p> <p>    Pharmacology of Insulin ..... 578</p> <p>Insulin Preparations ..... 578</p> <p>    Regular Insulin ..... 578</p> <p>    NPH or Isophane Insulin ..... 578</p> <p>    Lente Insulin ..... 579</p> <p>    Premixed Formulations ..... 579</p> <p>    Rapid Acting Analogues ..... 579</p> <p>    Long Acting Analogues ..... 579</p> <p>    Premixed Analogue Preparations ..... 579</p> <p>    Selection of Insulin ..... 579</p> <p>References ..... 581</p>
---	--

**Chapter - 34**

**Insulin and Oral Hypoglycemic Drugs**

<p>Diabetes Mellitus ..... 556</p> <p>    Classification of Diabetes Mellitus ..... 556</p> <p>    What Happens to Bodies when Hyperglycemic? ..... 556</p> <p>    Causes of Diabetes ..... 557</p> <p>    Pathophysiology ..... 557</p> <p>    Diagnosis and Diagnostic Tests ..... 558</p> <p>Complications of Diabetes ..... 559</p> <p>    Acute Complications of Diabetes ..... 559</p> <p>    Chronic Complications of Diabetes ..... 560</p> <p>    Microvascular (Microangiopathic) Disease ..... 560</p> <p>    Macrovascular Disease ..... 563</p> <p>    The Management of Diabetes ..... 564</p> <p>Treatment of Diabetes ..... 564</p> <p>    Treatment for Patients with Type 1 Diabetes ..... 564</p>
--

**Chapter - 35**

**Estrogens, Progestins and Androgens**

<p>Estrogens ..... 582</p> <p>    Biosynthesis ..... 583</p> <p>    Effects ..... 584</p> <p>    Therapeutic Uses ..... 586</p> <p>    Adverse Effects ..... 587</p> <p>Anti Estrogens and Estrogenic Modulators ..... 587</p> <p>    Inhibition of the Biosynthesis of Estrogens ..... 587</p> <p>    Inhibition of Estrogen Receptors, and SERM (Selective Estrogen Receptor Modulators) ..... 591</p> <p>    Fulvestrant ..... 595</p> <p>Progesterone and Progestins ..... 595</p> <p>    Progesterone ..... 596</p> <p>    Synthetic Progestins ..... 597</p>
--

Progesterone Antagonists ..... 599  
    Estroprogestative Combinations ..... 599  
Androgens ..... 602  
    Biosynthesis ..... 602  
    Distribution ..... 602  
    Biotransformations and Inactivation .... 603  
    Sexual Effects ..... 603  
    General Effects ..... 603  
    Sexual Therapeutic Uses ..... 604  
Anti Androgens ..... 605  
    Androgen Antagonists ..... 605  
References ..... 606

**Chapter - 36**

**Adrenal Hormones**

Introduction ..... 607  
Adrenocorticosteroids ..... 609  
    Glucocorticoids ..... 609  
    Mineralocorticoids ..... 612  
Antagonists of Adrenocortical Agents . 613  
    Synthesis Inhibitors and  
    Glucocorticoid Antagonists ..... 613  
    Mineralocorticoid Antagonists ..... 616  
References ..... 616

**PART VIII**

**DRUGS AFFECTING  
RESPIRATORY SYSTEMS**

**Chapter - 37**

**Drugs Used to Treat Asthma**

Introduction ..... 619  
    Asthma Triggers ..... 619  
    Diagnostic Testing ..... 619  
Adrenoceptor Agonists ..... 621  
    Salmeterol ..... 621  
    Albuterol ..... 622  
Anticholinergics ..... 622  
Methylxanthines ..... 622  
Anti Inflammatory Agents ..... 623  
    Corticosteroids ..... 624  
    Mast Cell-Stabilizing Agents ..... 626  
    Antileukotrienes ..... 627  
References ..... 629

**Chapter - 38**

**Drugs Used to Treat Allergic Rhinitis**

Definition ..... 630  
Diagnosis ..... 630  
    Paediatrics ..... 630  
    Testing ..... 630  
    Treatment ..... 632  
Pharmacological Therapy ..... 633  
    Intranasal Corticosteroids ..... 633  
    Oral Antihistamines ..... 633  
    Decongestants ..... 635  
    Leukotriene Inhibitors ..... 635  
    Anticholinergics ..... 635  
    Nasal Antihistamines ..... 637  
    Ocular Medications ..... 637  
    Nasal Saline ..... 637  
Immunotherapy ..... 637  
    Omalizumab (Xolair) ..... 638  
    Surgical Therapy ..... 639  
References ..... 639

**Chapter - 39**

**Drugs Used to Treat Cough,  
COPD and Cystic Fibrosis**

Cough ..... 640  
    Introduction ..... 640  
Treatment of Cough ..... 642  
    Antitussives (Central  
    Cough Suppressants) ..... 642  
    Expectorants ..... 643  
    Antihistamines ..... 645  
    Bronchodilators ..... 647  
Relief of Nasal Congestion and  
Other Cold Symptoms ..... 648  
    Sympathomimetic Drugs ..... 648  
    Pharyngeal Demulcents ..... 649  
    Traditional Cough and  
    Cold Remedies ..... 650  
    Recommendations for Management of a  
    Simple Cough or Cold or Sore Throat .... 650  
COPD (Chronic Obstructive  
Pulmonary Disease) ..... 651  
    Pathophysiology ..... 651

Chronic Bronchitis ..... 653  
 Emphysema ..... 654  
 Etiology of COPD ..... 654  
 Diagnosis of COPD ..... 654  
 Treatment of Chronic Obstructive  
 Pulmonary Disease ..... 655  
 Pharmacological Therapy of COPD  
 Exacerbations ..... 658  
 Cystic Fibrosis ..... 658  
 Epidemiology and Etiology ..... 659  
 Pathophysiology ..... 659  
 Clinical Presentation and Diagnosis .... 661  
 Laboratory Tests ..... 662  
 Treatment ..... 662  
 Nutrition ..... 663  
 Future Direction of Therapy ..... 668  
 References ..... 668

**PART IX**  
**DRUGS AFFECTING**  
**GASTROINTESTINAL TRACT**

**Chapter - 40**

**Drugs Used to Treat Peptic,  
 Ulcer Disease**

Classification by Region/Location ..... 671  
 Physiology of Acid Secretion ..... 672  
 Pathogenesis ..... 673  
 Signs and Symptoms ..... 674  
 Complications ..... 674  
 Differential Diagnosis ..... 674  
 Treatment ..... 674  
 Neutralization of Gastric Acid/  
 Antacids ..... 675  
 Reduction of Gastric Acid ..... 676  
 H<sub>2</sub>-Receptor Antagonists ..... 676  
 Proton Pump Inhibitors (PPIs) ..... 678  
 Prostaglandin Analogues ..... 680  
 Mucosal Protective Agents ..... 682  
 Sucralfate ..... 682  
 Colloidal Bismuth Compounds ..... 683  
 Surgery ..... 684  
 References ..... 684

**Chapter - 41**

**Drugs Used in Constipation**

Introduction ..... 686  
 Causes ..... 686  
 Primary ..... 686  
 Diet ..... 686  
 Medication ..... 686  
 Metabolic and Muscular ..... 686  
 Structural and Functional  
 Abnormalities ..... 686  
 Drugs Associated with Constipation .... 686  
 Treatment ..... 687  
 Non Pharmacological Measures ..... 687  
 Drugs Available to  
 Treat Constipation ..... 688  
 Bulk-Forming Laxatives ..... 689  
 Osmotic Laxatives ..... 689  
 Stimulant Laxatives ..... 689  
 Other Drugs ..... 691  
 Novel agents ..... 691  
 Serotonin 5-HT<sub>4</sub>-Receptor Agonists ..... 691  
 References ..... 692

**Chapter - 42**

**Emetics and Antiemetic Drugs**

Emesis (Vomiting) ..... 693  
 Control of Vomiting ..... 693  
 Causes ..... 694  
 Emetics ..... 695  
 Emetic Drugs ..... 695  
 Apomorphine ..... 695  
 Ipecacuanha ..... 695  
 Antiemetics ..... 696  
 Introduction ..... 696  
 Classification - Antiemetic Drugs ..... 696  
 H<sub>1</sub> Antihistamines and  
 Muscarinic Antagonists ..... 696  
 Selective 5-HT<sub>3</sub> Antagonists ..... 697  
 D<sub>2</sub> Antagonists ..... 697  
 Substituted Benzamides ..... 697  
 Phenothiazines ..... 699  
 Butyrophenones ..... 699  
 Cannabinoids (Dronabinol, Nabilone) . 699  
 Dronabinol ..... 699  
 Nabilone ..... 699

Glucocorticoids ..... 699  
    Dexamethasone, Methylprednisolone .. 699  
Benzodiazepines ..... 700  
    Diazepam, Lorazepam ..... 700  
Neurokinin-1 (NK<sub>1</sub>) Antagonists ..... 700  
    Aprepitant, Fosaprepitant ..... 700  
    Therapeutic Uses of Antiemetics ..... 701  
References ..... 702

**Chapter - 43**

**Drugs Used in Diarrhoea**

Introduction ..... 703  
Types of Diarrhoea ..... 703  
    Secretory Diarrhoea ..... 703  
    Osmotic Diarrhoea ..... 703  
    Exudative Diarrhoea ..... 703  
    Motility Related Diarrhoea ..... 703  
    Inflammatory Diarrhoea ..... 704  
    Dysentery ..... 704  
Differential Diagnosis ..... 704  
    Infections ..... 704  
    Malabsorption ..... 704  
    Irritable Bowel Syndrome ..... 705  
Treatment ..... 705  
    Oral Rehydration Therapy ..... 706  
Antimotility and Antisecretory Agents 706  
    Opioids ..... 706  
     $\alpha_2$  Adrenergic Receptor Agonists ..... 708  
    Otreotide and Somatostatin ..... 708  
Absorbent Agents ..... 708  
    Bulk-Forming and  
    Hydroscopic Agents ..... 708  
    Bile Acid Sequestrants ..... 709  
    Bismuth ..... 710  
    Other Agents ..... 710  
    Alternative Therapies ..... 710  
References ..... 714

**Chapter - 44**

**Digestants and GERD**

Digestants ..... 715  
    Examples of Digestants ..... 715  
    Digestants in Gastric Dysfunction ..... 716  
    Digestants in Pancreatic Insufficiency .. 716

GERD ..... 716  
    Pathophysiology ..... 716  
    Signs and Symptoms ..... 717  
    Diagnosis ..... 717  
    Treatment ..... 718  
    Antacids and Antacid-Alginic  
    Acid Products ..... 718  
    H<sub>2</sub>-Receptor Antagonists (H<sub>2</sub>RAs) ..... 719  
    Proton Pump Inhibitors (PPIs) ..... 719  
    Promotility Agents ..... 720  
References ..... 720

**PART X**

**DRUGS USED FOR OTHER THERAPIES**

**Chapter - 45**

**Drugs Used to Treat Erectile Dysfunction**

Introduction ..... 723  
    Physiology of Erection ..... 723  
    Clinical Features ..... 724  
    Causes of ED ..... 724  
    Diagnosis ..... 724  
Treatment ..... 725  
    Drug Therapy ..... 725  
Hypogonadism and Testosterone ..... 729  
    Replacement Therapy ..... 729  
    Vacuum Constriction Device ..... 729  
    Surgery ..... 729  
    Injectable Medications ..... 730  
    Psychotherapy ..... 732  
    Nonpharmacological Treatment ..... 732  
References ..... 733

**Chapter - 46**

**Drugs Used to Treat Osteoporosis**

Introduction ..... 734  
How Bones Work ..... 734  
    Signs ..... 734  
    Risk Factors ..... 734  
    Tests ..... 735  
Treatment ..... 735  
    Bisphosphonates ..... 735



Raloxifene .....	736
Calcitonin .....	736
Teriparatide .....	737
Denosumab .....	737
Estrogen/Hormone Therapy .....	737
Using Osteoporosis Therapies in Combination .....	738
New Treatments Coming up .....	741
References .....	741

## Chapter - 47

### Drugs Used to Treat Obesity

Definition .....	742
Etiology .....	742
Health Effects of Obesity .....	742
Diabetes (Type 2) .....	743
Hypertension .....	743
Cardiovascular Disease (CVD) .....	743
Stroke .....	743
Osteoarthritis (OA) .....	743
Sleep Apnea .....	743
Investigations .....	744
Treatment of Obesity .....	744
Behavior Modification .....	744
Pharmacotherapy .....	745
Lorcaserin .....	747
Other Appetite Suppressants .....	748
Surgical Intervention .....	748
References .....	750

## PART XI

### BIOGENIC AMINES AND POLYPEPTIDES

## Chapter - 48

### Histamine and Antihistamines

Introduction .....	753
Chemistry and Pharmacokinetics .....	753
Release .....	754
Types of Histamine	
Receptors .....	754
Mechanism of Action .....	755
Conditions that Release Histamine .....	755
Tissue and Organ System	
Effects of Histamine .....	756
Nervous System .....	756

Cardiovascular System .....	756
Bronchiolar Smooth Muscle .....	756
Gastrointestinal Tract Smooth Muscle ..	756
Other Smooth Muscle Organs .....	756
Secretory Tissue .....	756
Metabolic Effects .....	757
Triple Response .....	757
Clinical Uses .....	757
Toxicity and Contraindications .....	757
Histamine Antagonists .....	757
Basic Pharmacology of	
H <sub>1</sub> -Receptor Antagonists .....	757
H <sub>2</sub> Receptor Antagonists .....	762
H <sub>3</sub> Receptor Drugs .....	763
H <sub>4</sub> Receptor Antagonists .....	763
Inhibitors of Histamine Release .....	763
References .....	764

## Chapter - 49

### 5-Hydroxytryptamine, its Agonists and Antagonists

Introduction .....	765
Distribution (PNS) .....	765
Synthesis and Metabolism .....	765
Carrier Mediated Uptake .....	765
Drugs Affecting on	
Tryptaminergic System .....	765
Mechanisms of Action .....	766
Tissue and Organ System Effects .....	770
Nervous System .....	770
Respiratory System .....	771
Cardiovascular System .....	771
Gastrointestinal Tract .....	771
Other Systems .....	771
Serotonin Syndrome .....	771
Serotenergic Drugs .....	772
Serotonin Agonists .....	772
Serotonin Antagonists .....	774
Migraine .....	775
General Treatment Principles .....	776
Nonspecific Acute Treatment .....	776
Neuroleptics/Antiemetics .....	777
Specific Acute Treatment-Triptans .....	778

Specific Migraine Preventive Agents ..... 779  
Other Preventive Agents ..... 781  
References ..... 782

**Chapter - 50**

**Angiotensin, Kinins, Leukotrienes,  
Prostaglandins, Cytokines,  
Nitric Oxide and Platelet activating  
Factor Angiotensin**

Angiotensin ..... 783  
Angiotensinogen ..... 783  
  Angiotensin I ..... 783  
  Angiotensin II ..... 783  
  Angiotensin III ..... 784  
  Angiotensin IV ..... 784  
  Effects ..... 784  
  Angiotensin Receptors and  
  Mechanism of Action ..... 785  
Drugs Acting on Renin  
Angiotensin Aldosterone System ..... 786  
  ACE Inhibitors ..... 786  
  Angiotensin II Receptor Antagonists .... 792  
  Renin Inhibitors ..... 794  
Types of Kinins ..... 796  
  Kallikrein-Kinin System ..... 796  
  Kallikreins ..... 796  
  Effects of Kinins ..... 796  
Leukotrienes ..... 798  
  History and Name ..... 798  
  Control and Regulation ..... 798  
  Enzymatic Control ..... 800  
  Types ..... 801  
  Functions of Leukotrienes ..... 801  
  Leukotrienes in Asthma ..... 802  
  Types of Anti-leukotriene Drugs ..... 802  
Prostaglandins ..... 803  
  History and Name ..... 803  
  Types of PGs ..... 804  
Biosynthetic Pathways ..... 804  
  PG Receptors ..... 805  
  Cyclooxygenases ..... 806  
  Functions ..... 807  
  Role in Pharmacology ..... 809  
  Effects of Aspirin and  
  other Pain Killers ..... 809  
  Non-steroidal Anti-inflammatory  
  Drugs (NSAIDs) ..... 810

Cytokines ..... 810  
  Properties of Cytokines ..... 810  
  Classification of Cytokines ..... 811  
  Cytokine Receptors ..... 814  
  Function of Cytokines ..... 814  
Nitric Oxide ..... 815  
Introduction ..... 815  
  The Structure and Nature of  
  Nitric Oxide ..... 815  
  Synthesis of Nitric Oxide ..... 815  
  Activation of NOS ..... 816  
    Role of Nitric Oxide in the  
    Human Body ..... 817  
Platelet Activating Factor ..... 822  
  Chemistry and Biology ..... 822  
  Biosynthesis ..... 823  
  Biochemical Function ..... 823  
  Pharmacological Properties ..... 825  
  Mechanism of Action of PAF ..... 825  
  Physiological and  
  Pathological Functions of PAF ..... 825  
  Role in Pharmacology ..... 826  
  References ..... 826

**PART XII**

**CHEMOTHERAPEUTIC DRUGS**

**Chapter - 51**

**Sulfonamides, Trimethoprim and  
Cotrimoxazole**

Sulfonamides ..... 831  
  Antibacterial Spectrum ..... 833  
  Classification ..... 833  
  General Properties ..... 833  
  Metabolism and Excretion ..... 836  
  Trimethoprim-Sulfamethoxazole ..... 838  
  Gastrointestinal Infections ..... 840  
  Respiratory Infections ..... 842  
  References ..... 844

**Chapter - 52**

**Cell Wall Inhibitors**

Classification of Agents Affecting Cell  
Wall Synthesis ..... 845  
 $\beta$ -Lactam Antibiotics ..... 846

Penicillin's .....	848
General Properties .....	848
Classification .....	848
Penicillins .....	848
Mechanisms of Resistance .....	850
Natural Penicillins .....	851
Antistaphylococcal (Penicillinase-Resistant) Penicillins .....	851
Aminopenicillins .....	852
Antipseudomonal Penicillins .....	852
Cephalosporins .....	855
Classification .....	855
Antimicrobial Activity .....	857
Pharmacokinetic Features .....	858
Clinical Uses .....	858
Monobactams .....	860
$\beta$ -lactamase Inhibitors (Clavulanic Acid, Sulbactam and Tazobactam) .....	860
$\beta$ -Lactamase Inhibitors .....	860
$\beta$ -Lactamase Inhibitors in Clinical Practice .....	861
Carbapenems .....	864
Other Cell Wall Synthesis Inhibitors .....	865
Vancomycin and Teicoplanin .....	865
Bacitracin .....	866
References .....	867

**Chapter - 53**

**Protein Synthesis Inhibitors**

Aminoglycosides .....	868
Classification .....	868
Microbial Resistance .....	870
Kinetics .....	871
Toxicity .....	872
Drug Interactions .....	872
Heparin .....	872
Individual Agents .....	872
Streptomycin .....	872
Gentamicin .....	873
Tobramycin .....	873
Amikacin .....	873
Netilmicin .....	873
Kanamycin and Neomycin .....	873
Spectinomycin .....	873

Tetracyclines .....	874
Classification .....	874
Origin .....	874
Chloramphenicol .....	878
Macrolides .....	879
Clindamycin/Lincomycin .....	883
Streptogramins .....	884
Quinupristin-Dalfopristin (Synercid) .....	884
References .....	885

**Chapter - 54**

**Quinolones and Urinary Antiseptics**

Quinolones .....	886
Introduction .....	886
Resistance to Quinolones .....	890
Therapeutic Uses of Quinolones .....	890
Genitourinary Infections .....	890
Prostatitis .....	891
Respiratory Diseases .....	891
Sexually Transmitted Diseases .....	892
Gastroenteritis .....	892
Skin and Soft Tissue Infections .....	893
Urinary Antiseptics .....	895
Methenamine .....	895
Nitrofurans (Nitrofurantoin) .....	895
Fosfomycin .....	897
References .....	897

**Chapter - 55**

**Antimycobacterials**

Tuberculosis .....	898
Transmission .....	898
Signs and Symptoms .....	898
Cause .....	898
Drugs {Multiple Drug Therapy} .....	899
Isoniazid .....	901
Rifampicin .....	902
Ethambutol .....	903
Pyrazinamide .....	903
Streptomycin .....	904
Cycloserine .....	904
DOTS .....	905
Prevention .....	905

Leprosy ..... 905  
    Introduction ..... 905  
    Classification Schemes for Leprosy ..... 906  
Tuberculoid/Paucibacillary ..... 907  
    Lepromatous/Multibacillary ..... 907  
    Physical Findings in  
    Lepromatous Disease ..... 907  
    Borderline (Dimorphous) ..... 908  
    Indeterminate Leprosy ..... 908  
Bone Changes in Leprosy ..... 908  
    Transmission of Leprosy ..... 908  
    Diagnostic Tests ..... 908  
Histological Testing ..... 909  
Clofazamine ..... 910  
Dapsone ..... 911  
    MDT Side-Effects ..... 911  
    Complications of Medical Therapy ..... 911  
    Surgical Treatments ..... 911  
References ..... 912

**Chapter - 56**

**Antifungal Drugs**

Introduction ..... 913  
    Types of Fungal Infections - Mycoses .... 913  
Classification of Antifungals ..... 914  
Azole Antifungals for  
Systemic Infections ..... 914  
    Azoles - Mechanism ..... 915  
Ketoconazole ..... 915  
Fluconazole ..... 917  
Itraconazole ..... 918  
Voriconazole ..... 918  
Posaconazole ..... 918  
Amphotericin B ..... 918  
Flucytosine ..... 920  
Squalene Epoxidase Inhibitors ..... 921  
    Terbinafine ..... 921  
Griseofulvin ..... 922  
Nystatin ..... 922  
Ciclopirox ..... 922  
Tolnaftate ..... 923  
    Cell Wall Inhibitors ..... 923  
    Spectrum ..... 923  
Undecylenic Acid ..... 924  
References ..... 925

**Chapter - 57**

**Antiprotozoal Drugs**

Protozoal Infections ..... 926  
Malaria ..... 926  
    Cause ..... 926  
    Parasite Life Cycle ..... 926  
    Classification of Anti Malarial Drugs  
    according to Site of Action ..... 927  
Chloroquine ..... 928  
Amodiaquine ..... 929  
Piperaquine ..... 930  
Artemisinin (Qinghaosu)  
and its Derivatives ..... 930  
Quinine and Quinidine ..... 931  
Mefloquine ..... 932  
Primaquine ..... 932  
Atovaquone ..... 933  
Pyrimethamine ..... 934  
Proguanil: Chloroguanide ..... 935  
Antibiotics ..... 935  
    Doxycycline ..... 935  
Halofantrine and Lumefantrine ..... 936  
    Combination Therapy for  
    Chloroquine Resistant Malaria ..... 937  
    Treatment of Complicated  
    P. falciparum ..... 937  
Anti-Amoebic Drugs ..... 937  
    Life Cycle of E. histolytica ..... 937  
Therapeutic Classification of  
Anti-Amoebic Drugs ..... 938  
Metronidazole (Flagyl) ..... 938  
Tinidazole ..... 940  
Emetine ..... 940  
Chloroquine ..... 941  
Diloxanide Furoate  
(Luminal Amebicidal) ..... 941  
Iodoquinol ..... 942  
Antibiotics ..... 942  
    Paromomycin Sulphate ..... 942  
    Tetracyclines ..... 943  
    Treatment of Specific  
    Forms of Amebiasis ..... 943  
Chemotherapy for Trypanosomiasis ..... 943  
    Treatment ..... 943

Melarsoprol ..... 943  
 Pentamidine Isethionate ..... 944  
 Nifurtimox ..... 945  
 Suramin ..... 945  
 Benznidazole ..... 946  
 Chemotherapy for Leishmaniasis ..... 946  
     Life Cycle of the Causative  
     Organism: Leishmania Species ..... 946  
     Treatment ..... 946  
 Chemotherapy for Toxoplasmosis ..... 947  
     Chemotherapy for Giardiasis ..... 947  
 References ..... 947

**Chapter - 58**

**Anthelmintic Drugs**

Helmintic Infections ..... 948  
     Types of Worms ..... 948  
     Intestinal Worms ..... 948  
 Anthelmintic Drugs ..... 948  
     Classification ..... 949  
     Piperazine ..... 949  
     Albendazole ..... 950  
     Benzimidazoles ..... 950  
     Mebendazole ..... 951  
     Thiabendazole ..... 951  
     Diethylcarbamazine ..... 952  
     Niclosamide ..... 952  
     Ivermectin ..... 953  
     Suramin ..... 954  
     Pyrantel Pamoate ..... 955  
     Paraherquamide ..... 956  
     Praziquantel ..... 956  
     Oxamniquine ..... 957  
     Bithionol ..... 957  
     Metrifonate ..... 957  
     Emodepside ..... 958  
     Nitazoxanide ..... 959  
 References ..... 959

**Chapter - 59**

**Antiviral Drugs**

Introduction ..... 960  
     Research in Antiviral Chemotherapy .... 960  
     Antiviral Agents ..... 960

Antiviral Drugs: General Features ..... 963  
     Amantadine and Congeners ..... 963  
 Ribavirin ..... 965  
 Acyclovir and Congeners ..... 966  
 Vidarabine ..... 968  
 Idoxuridine and Trifluridine ..... 969  
     Idoxuridine ..... 969  
     Trifluridine ..... 969  
 Foscarnet ..... 970  
 Zidovudine ..... 971  
 Deoxynucleosides used in AIDS ..... 972  
     Stavudine ..... 972  
     Didanosine ..... 972  
     Lamivudine ..... 973  
     Abacavir ..... 973  
     Zalcitabine ..... 973  
     HIV Protease Inhibitors ..... 974  
     Saquinavir ..... 974  
     Ritonavir ..... 974  
     Indinavir ..... 975  
     Nelfinavir ..... 975  
     Amprenavir ..... 975  
     Lopinavir-Ritonavir ..... 975  
     Entry Inhibitors ..... 975  
     Interferon's ..... 975  
 References ..... 976

**Chapter - 60**

**Anticancer Drugs**

Introduction ..... 977  
 Cell Cycle Specific Agents and  
 Cell Cycle Non Specific Agents ..... 978  
 Mechanism of Anticancer Drugs ..... 978  
 Classification of Anticancer Drugs ..... 978  
 Nitrogen Mustards ..... 983  
     Mechlorethamine ..... 983  
 Cyclophosphamide ..... 983  
 Ifosfamide ..... 984  
 Chlorambucil ..... 985  
 Nitrosoureas ..... 985  
 Streptozocin ..... 985  
 Alkyl Sulfonates ..... 986  
     Busulfan ..... 986



**Chapter - 63**

**Drugs Used to Treat Psoriasis and Acne Vulgaris**

Psoriasis ..... 1033  
 Causes and Risk Factors ..... 1033  
 Symptoms ..... 1033  
 Classification ..... 1033  
 Nonpustular ..... 1034  
 Pustular ..... 1034  
 Other ..... 1034  
 Diagnosis ..... 1034  
 Treatment ..... 1035  
 Nonpharmacological Therapy ..... 1035  
 Emollients (Moisturizers) ..... 1035  
 Balneotherapy (and Climatotherapy).. 1035  
 First-Line Topical Pharmacotherapy ... 1035  
 Keratolytics ..... 1035  
 Corticosteroids ..... 1035  
 Topical Corticosteroids ..... 1035  
 Vitamin D Analogues ..... 1036  
 Calcipotriene ..... 1036  
 Tazarotene ..... 1036  
 Tazarotene (Tazorac) ..... 1036  
 Second-Line Topical  
 Pharmacotherapy ..... 1037  
 Coal Tar ..... 1037  
 Anthralin ..... 1037  
 First-Line Systemic  
 Pharmacotherapy ..... 1037  
 Infliximab ..... 1037  
 Etanercept ..... 1038  
 Adalimumab ..... 1038  
 Alefacept ..... 1038  
 Efalizumab ..... 1038  
 Second-Line Systemic  
 Pharmacotherapy ..... 1039  
 Acitretin ..... 1039  
 Cyclosporine ..... 1039  
 Tacrolimus ..... 1039  
 Methotrexate ..... 1039  
 Mycophenolate Mofetil ..... 1040  
 Sulfasalazine ..... 1040

Phototherapy and  
 Photochemotherapy ..... 1041  
 Hydroxyurea ..... 1041  
 Acne Vulgaris ..... 1042  
 Nonpharmacological Therapy ..... 1042  
 Topical Pharmacotherapy ..... 1043  
 Benzoyl Peroxide ..... 1043  
 Tretinoin ..... 1043  
 Adapalene ..... 1043  
 Tazarotene ..... 1044  
 Erythromycin ..... 1044  
 Clindamycin ..... 1044  
 Azelaic Acid ..... 1044  
 Salicylic Acid, Sulfur and Resorcinol.. 1044  
 Systemic Pharmacotherapy ..... 1044  
 Isotretinoin ..... 1044  
 Oral Antibacterial Agents ..... 1045  
 Oral Contraceptives ..... 1045  
 References ..... 1046

**PART XIV  
 TOXICOLOGY**

**Chapter - 64**

**Introduction to Toxicology**

Manifestations of Toxicity ..... 1049  
 Organ Toxicity ..... 1049  
 Pulmonary Toxicity ..... 1049  
 Hepatotoxicity ..... 1050  
 Nephrotoxicity ..... 1051  
 Neurotoxicity ..... 1051  
 Immunotoxicity ..... 1051  
 Insecticides ..... 1054  
 Herbicides and Rodenticides ..... 1054  
 References ..... 1055

**Chapter - 65**

**Heavy Metal Intoxication and Chelators**

Definitions ..... 1056  
 Heavy Metal ..... 1056  
 Lead ..... 1056  
 Arsenic ..... 1058  
 Cadmium ..... 1059  
 Mercury ..... 1061

Chelating Agents .....	1061	Diagnosis .....	1085
Introduction .....	1061	Treatment .....	1085
Characteristics of an Ideal Chelator ....	1062	Disease Modifying	
Common Chelating Agents:		Antirheumatic Drugs .....	1085
Pharmacology and Toxicology .....	1062	Methotrexate .....	1085
Calcium Disodium Ethylenediamine		Basic Pharmacology .....	1086
Tetraacetic Acid (CaNa <sub>2</sub> EDTA) .....	1062	Sulfasalazine .....	1086
Calcium Trisodium DTPA .....	1064	Antimalarials .....	1087
D-Penicillamine .....	1065	Leflunomide .....	1088
British Anti Lewisite (BAL) .....	1065	Etanercept .....	1089
Meso-2,3-Dimercaptosuccinic		Interleukin-1 Antagonists .....	1090
Acid (DMSA) .....	1066	Gold Compounds .....	1091
Sodium 2,3 Dimercaptopropane-l-		Azathioprine .....	1092
Sulphonate (DMPS) .....	1067	Cyclosporine .....	1092
New DMSA Analogues .....	1067	Cyclophosphamide .....	1093
Monoisoamyl DMSA (MiADMSA) .....	1068	Minocycline .....	1093
Monomethyl DMSA (MmDMSA) and		Penicillamine .....	1094
Monocyclohexyl DMSA (MchDMSA) .	1068	Combination Therapy .....	1094
Deferoxamine (DFO) .....	1069	Gout .....	1094
Deferiprone (L1) .....	1069	Causes .....	1095
TETA .....	1070	Drugs that causes Hyperuricemia .....	1095
Nitrilotriacetic Acid (NTA) .....	1070	Treatment .....	1095
References .....	1071	NSAIDs .....	1095

## PART XV

### Miscellaneous

#### Chapter - 66

##### Management of the Poisoned Patient

Introduction .....	1075
Clinical Evaluation .....	1075
General Management .....	1077
Diagnostic Adjuncts .....	1078
Gastrointestinal Decontamination .....	1079
Disposition .....	1080
A General Approach to the	
Treatment of Acute Poisoning .....	1081
References .....	1082

#### Chapter - 67

##### Drugs Used to

##### Treat Rheumatoid Arthritis and Gout

Rheumatoid Arthritis (RA) .....	1083
Pathogenesis .....	1083
Signs and Symptoms .....	1085

#### Chapter - 68

##### Drugs that Affect Uterine Function

Preterm Birth .....	1102
Uterine Stimulants (Oxytocics) .....	1102
Oxytocin (Syntocinon) .....	1103
Synthesis .....	1103
Ergot Alkaloids .....	1104
Prostaglandins (PGE <sub>2</sub> & PGF <sub>2a</sub> ) .....	1105
Uterine Relaxants .....	1107
Ethanol .....	1107
β <sub>2</sub> Adrenoceptor Agonists .....	1107



Terbutaline .....	1108
Magnesium Sulfate .....	1108
Other Agents .....	1108
Drugs Used to Promote Cervical Ripening .....	1109
References .....	1109

## Chapter - 69

### Immunosuppressants and Immunostimulants

Introduction .....	1110
Cell-mediated Immunity .....	1110
Humoral Immunity .....	1111
Immunosuppressant Drugs .....	1111
Cyclosporine .....	1112
Tacrolimus (Fk506) .....	1113
Differences between CsA and TAC ...	1114
Corticosteroids .....	1115
Azathioprine .....	1117
Mycophenolate Mofetil .....	1117
Leflunomide .....	1119
Methotrexate .....	1119
Antilymphocyte Globulins (ALG) and Antithymocyte Globulins (ATG) .....	1119
Muromonab-CD3 .....	1119
Rh <sub>0</sub> (D) Immune Globulin .....	1121
Basiliximab and Daclizumab .....	1121
Infliximab .....	1121
Omalizumab .....	1121
Interferons .....	1121
Thalidomide .....	1122
Immunostimulants .....	1123
Bacillus Calmette-Guérin .....	1123
Levamisole .....	1124
Thymic Factors .....	1124
Cytokines .....	1124
Myeloid Colony-Stimulating Factors .	1125
Other Cytokines .....	1125
References .....	1125

## Chapter - 70

### Vitamins, Minerals and Antioxidants

Introduction .....	1126
Classification .....	1127
Fat Soluble Vitamins .....	1127

Vitamin A (precursor - beta carotene) .....	1128
Vitamin D .....	1130
Vitamin E .....	1130
Vitamin K .....	1131
Water Soluble Vitamins .....	1131
Vitamin B <sub>1</sub> .....	1133
Vitamin B <sub>2</sub> .....	1133
Vitamin B <sub>3</sub> .....	1134
Vitamin B <sub>5</sub> .....	1134
Vitamin B <sub>6</sub> .....	1134
Vitamin B <sub>7</sub> .....	1135
Vitamin B <sub>9</sub> .....	1136
Biochemistry of DNA	
Base and Amino Acid Production .....	1136
Conversion to Biologically .....	1136
Active Derivatives .....	1136
Vitamin B <sub>12</sub> .....	1137
Vitamin C .....	1137
Minerals .....	1139
Major and Trace Minerals .....	1140
Uses of Minerals .....	1140
Major Minerals .....	1140
Trace Minerals .....	1142
Antioxidants .....	1145
Mechanisms of Metals in	
Accelerating Lipid Oxidation .....	1145
Factors Affecting the	
Efficiency of Antioxidants .....	1147
Choices of Antioxidants .....	1147
References .....	1149

## Chapter - 71

### Drug Therapy in Pregnancy

Pharmacokinetics .....	1151
Lipid Solubility .....	1151
Molecular Size .....	1151
Placental Transporters .....	1151
Protein Binding .....	1152
Placental and Fetal Drug Metabolism .	1152
Pharmacodynamics .....	1152
Maternal Drug Actions .....	1152
Therapeutic Drug Actions in the Fetus .....	1153

Predictable Toxic Drug  
Actions in the Fetus ..... 1153  
Teratogenic Drug Actions ..... 1153  
Teratogenic Mechanisms ..... 1153  
Defining a Teratogen ..... 1155  
FDA Pregnancy Categories ..... 1157  
References ..... 1163

**Chapter - 72**

**Drugs Use during Lactation**

Lactation ..... 1164  
References ..... 1168

**PART XVI**

**PHARMACOLOGY GATE AND  
GPAT PREVIOUS QUESTIONS**

**Chapter - 73**

**Multiple Choice, Linked and Match the  
Following Questions of Previous GATE  
and GPAT Examinations along with  
Answers**

Multiple Choice Questions ..... 1171  
Two Options Correct Questions ..... 1181  
Data Based Questions ..... 1184  
Several Drugs are used for Migraine ... 1185  
Statement for Linked  
Answer Questions ..... 1185  
Match the Pairs ..... 1187

**APPENDIXES**

**Appendix - 1**

**Gene Therapy**

Introduction ..... 1195  
Principles of Gene Therapy ..... 1195  
How does Gene Therapy Work? ..... 1195  
What Gene Therapy can Achieve ..... 1196  
Types ..... 1199  
Methods of Gene Delivery ..... 1199  
Various Strategies for Gene Therapy ... 1199  
Gene Therapy Vectors ..... 1200  
Viruses ..... 1200  
Retroviruses ..... 1200  
Adenoviruses ..... 1200

Adeno Associated Viruses ..... 1201  
Envelope Protein Pseudotyping of  
Viral Vectors ..... 1201  
Replication Vectors ..... 1202  
Cis and Trans Acting Elements ..... 1202  
Herpes Simplex Virus ..... 1202  
Naked DNA ..... 1202  
Oligonucleotides ..... 1202  
Lipoplexes and Polyplexes ..... 1203  
Hybrid Methods ..... 1204  
Dendrimers ..... 1204  
What is the Current Status of  
Gene Therapy Research? ..... 1204  
References ..... 1206

**Appendix 2**

**Drug Discovery and Development**

Introduction ..... 1207  
The Discovery Process ..... 1207  
Pre Discovery ..... 1207  
Target Identification ..... 1207  
Target Prioritization/Validation ..... 1207  
Lead Identification ..... 1208  
Lead Optimization ..... 1208  
Early Safety Tests ..... 1208  
Lead Optimization ..... 1208  
Preclinical Testing ..... 1209  
The Development Process ..... 1209  
Clinical Trial Design ..... 1209  
Phase 1 Clinical Trial ..... 1210  
Phase 2 Clinical Trial ..... 1210  
Phase 3 Clinical Trial ..... 1210  
New Drug Application (NDA) and  
Approval ..... 1210  
Submit Application for  
Approval to FDA ..... 1210  
Benefit Vs. Risk ..... 1211  
Manufacturing ..... 1211  
Ongoing Studies and Phase 4 Trials ... 1211  
Conclusion ..... 1214  
References ..... 1214

**Appendix - 3**

**Abnormal Actions of Drugs**

Adverse Drug Event ..... 1215  
The Risk to Benefit Ratio ..... 1215

Classification ..... 1216  
 Predictable Reactions (Type A) ..... 1216  
 Seriousness and Severity ..... 1216  
 Unpredictable Reactions (Type B) ..... 1216  
 Overall Drug Risk ..... 1217  
 Location ..... 1217  
 Mechanisms ..... 1217  
 Abnormal Pharmacokinetics ..... 1217  
 Detecting Adverse Effects ..... 1219  
 Prevention of Adverse  
 Drug Reactions ..... 1219  
 Hypersensitivity ..... 1219  
 Drug Habitation ..... 1223  
 Drug Allergy ..... 1223  
 References ..... 1226

**Appendix - 4**

**Classifications of Medications**

Introduction ..... 1227  
 Medication Classifications ..... 1227  
 Drug Classification ..... 1240

**Appendix - 5**

**Drug Interactions**

Definition ..... 1270  
 Prevalence ..... 1270  
 Factors Contributing to  
 Drug Interactions ..... 1270  
 Mechanisms of Drug Interaction ..... 1271  
 Drug Distribution Interactions ..... 1273  
 Protein-binding Interactions ..... 1273  
 Drug Excretion Interactions ..... 1275  
 Drug Food Interactions ..... 1285  
 Reducing the Risk of Drug Interactions -  
 Principles of Drug  
 Interactions Management ..... 1290  
 References ..... 1291

**Index ..... 1293**